![]() ![]() ![]() Bishop is currently Professor of Medicine and Director, the David and Etta Jones Center for Cellular Therapy at the University of Chicago, a leading cellular therapy program in the United States.ĭr Bishop is a widely recognized as an expert in hematopoietic stem cell transplant and cellular therapy research and patient care, with a focus on leukemias and lymphomas. She completed a residency at the Mayo Clinic College of Medicine in Rochester, MN, followed by a hematology and medical oncology fellowship. Dr Lin is also the author of over a hundred publications, including many pivotal cell therapy consensus statements and practice guidelines.ĭr Lin is a key committee member of SITC (Society for Immunotherapy for Cancer), the IMWG (International Working Group on Myeloma), CIBMTR (Centre for International Blood and Marrow Transplant Research) and iwCART, the International Workshop on CAR T.ĭr Lin completed her medical training at the Northwestern University Feinberg School of Medicine in Chicago, IL. ![]() Since leaving academic medicine almost 15 years ago, Dr Litten has been dedicated to developing new medicines for cancer patients in the biotech and pharmaceutical field.ĭr Lin is currently the Chair of the Cellular Therapeutics Cross Disciplinary group at Mayo Clinic Cancer Center, an Associate Professor of Medicine, and a consultant in theĭivision of Hematology and the Division of Experimental Pathology at the Mayo Clinic in Rochester, MN.ĭr Lin is a pioneer in cellular immunotherapy having participated in many of the fi rst in human CAR T cell therapy trials and multiple phase 2 cellular immunotherapyĬlinical trials. After medical school, he completed a Residency in General Pediatrics at University of Miami and a Clinical Fellowship in Pediatric Hematology & Oncology at UT Southwestern. Jason holds a BS from Cornell University and MD from Emory University. Jason started his industry career in Oncology Clinical Development at Amgen Inc. Before Juno, he was Vice President of Clinical Development at Clovis Oncology. Prior to Artiva, Jason was the Vice President of Clinical Development overseeing Solid Tumor Programs at Juno Therapeutics. During his time at Artiva, Jason contributed to launching two clinical NK cell therapy programs, raising over $200 million in private financing andĮstablishing two foundational corporate partnerships. Jason joined Chimeric after serving as the Chief Medical Officer at Artiva Biotherapeutics where led built and led Artiva’s clinical and regulatory functions. Jason also has experience leading the clinical and preclinical development of numerous therapeutic monoclonal antibodies and orally available cancer medicines. Jason is an expert in cell therapy and clinical oncology with experience developing some of the first CAR T, TCR and NK cell clinical programs. Jason B Litten MD is the Chief Medical Officer at Chimeric Therapeutics. CHM 0301 (Next Generation CORE-NK Platform). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |